V001-BCMA / Tongji Hospital, Cancer Hospital of Chinese Academy of Medical Sciences - LARVOL DELTA

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Tongji Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • ANCA Vasculitis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P1 trial • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Small Cell Lung Cancer • Solid Tumor • DLL3